RECOMBINANT FUSED HUMAN PROTEIN EPO-FC WITH PROLONGED TIME OF HALF-LIFE AND INCREASED ERYTHROPOETIC ACTIVITY IN VIVO (VERSIONS), DIMERIC PROTEIN CONSTRUCTION, DIMERIC PROTEIN, PHARMACEUTICAL COMPOSITION, SEQUENCE OF NUCLEIC ACID (VERSIONS), EXPRESSION VECTOR, CELL, METHOD OF OBTAINING PROTEIN AND METHOD OF ERYTHROPOESIS STIMULATION IN MAMMAL Russian patent published in 2011 - IPC C12N15/13 C12N15/18 C12N15/62 C12N15/63 C07K14/505 C07K16/18 C07K19/00 C12P21/02 A61K38/18 A61K47/42 A61K47/48 A61P7/00 

FIELD: medicine.

SUBSTANCE: by recombinant method obtained is fused protein, which contains natural molecule of human erythropoetine with cysteine residue near its C-end and Fc fragment of humal IgG, containing hinge region, N-end of said Fc fragment is connected to said C-end of said erythropoetine molecule, and said Fc fragment is natural, excluding mutation, consisting in substitution of cysteine residue in said hinge region, located the nearest of all to said erythropoetine molecule, with non-cysteine residue, which resulted in the fact that first cysteine residue of said hinge region, located the nearest of all to said N-end, is separated, by, at least, 12 or 17 amino acids from said cysteine residue of said erythropoetine molecule. Obtained peptide is used for stimulation of erythropoesis in mammal.

EFFECT: invention makes it possible to obtain fused protein, which possesses erythropoetine activity, has prolonged time of half-life in vivo in comparison with native human erythropoetine.

43 cl, 20 dwg, 10 ex